No Data
Biocytogen Pharmaceuticals Grants Worldwide License for Anti-Tumor Therapy
PacBio-Sequencing-B (02315.HK): IDEAYA nominates B7H3/PTK7 heteromeric enzyme inhibitors with similar first-class potential as effective payload dual-specificity ADC (IDE034) as a development candidate drug and exercises its right of selection.
Grassroots on November 11th, Bai Aosai Tu-B (02315.HK) announced that IDEAYA Biosciences, Inc. (nasdaq: IDYA) (IDEAYA), a precision medical company dedicated to discovering and developing targeted therapeutic drugs for tumors, has exercised its option to obtain the global exclusive license of B7H3/PTK7 topoisomerase inhibitor payload dual-specificity antibody conjugate drug (BsADC) BCG034 (IDE034) with similar first-in-class potential to Bai Aosai Tu, and has nominated the project as a development candidate drug.
Beijing Enterprises Water Group Ltd. - B (02315.HK) received shareholding of 1 million H shares from Vico (Hong Kong) Economic and Trade Limited, with a value of approximately 5.85 million Hong Kong dollars.
Reported on November 1st, according to the documents disclosed by the Hong Kong Stock Exchange on November 1st, VK (Hong Kong) Trade and Industry Co., Ltd. increased its shareholding of $1 million H-shares of Paxon-B (02315.HK) at an average price of HK$5.85 per share on October 31, worth approximately HK$5.85 million. After the shareholding increase, the latest number of shares held by VK (Hong Kong) Trade and Industry Co., Ltd. is 8.1026 million shares, and the holding ratio has increased from 6.41% to 7.31%. Image Source: Stock Exchange Equity Disclosure. What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their equity.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
BIOCYTOGEN-B: 2024 Interim Report
Baosight-B (02315.HK) received a shareholding of 0.7 million shares of H-shares from WiCo (Hong Kong) Trade & Investment Limited, with a value of approximately 4.095 million Hong Kong dollars.
Reported on September 12th, according to the documents disclosed by the Hong Kong Stock Exchange on September 12th, Veeko (Hong Kong) Trade and Commerce Co., Ltd. increased its shareholding of $Biosat-B(02315.HK)$ by an average of 5.85 Hong Kong dollars per share on September 11th, with a total of 0.7 million H shares, worth approximately 4.095 million Hong Kong dollars. After the shareholding, the latest shareholding number of Veeko (Hong Kong) Trade and Commerce Co., Ltd. is 7.1026 million shares, and the holding ratio has increased from 5.78% to 6.41%. Image Source: Stock Exchange Equity Disclosure. What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) must disclose their equity.
No Data
No Data